HP
TVRD

Harbourvest Partners’s Tvardi Therapeutics TVRD Stock Holding History

Harbourvest Partners’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,874
Closed -$672K – 24
2014
Q4 		$672K Buy
+1,874
New +$604K 0.35% 19

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DPA
Devon Park Associates $30.8M AUM 0.85% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Harbourvest Partners's TVRD Position: Q1 2015 in Review

Harbourvest Partners sold out of Tvardi Therapeutics (TVRD) in Q1 2015, closing a stake of 1,874 shares — an estimated $672K sold.

Harbourvest Partners first reported a position in TVRD in Q4 2014 and held it in 1 quarter. The position peaked at $672K in Q4 2014. 60 funds tracked by Wall St. Rank hold TVRD as of Q1 2015.

  • Harbourvest Partners reported no remaining Tvardi Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Harbourvest Partners sold 1,874 Tvardi Therapeutics shares in Q1 2015, an estimated $672K.
  • Harbourvest Partners first reported a position in Tvardi Therapeutics in Q4 2014 and held it in 1 quarter.
  • Harbourvest Partners's Tvardi Therapeutics position peaked at $672K in Q4 2014.
  • 60 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2015.

Based on Harbourvest Partners's 13F filing for Q1 2015, filed 8 May 2015.